Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene Mutations or Wild-Type Transthyretin Amyloidosis.

NCT00628745 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00628745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00628745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene Mutations or Wild-Type Transthyretin Amyloidosis.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 4, 2008
Completion date
June 19, 2023
Enrollment
6,718 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloidosis, transthyretin gene mutations